Abstract
Patients treated with targeted therapy for metastatic renal carcinoma often benefit from sequential therapy with several agents used in succession. Several randomised and nonrandomised studies have been published that offer some insight into optimal choice for 2nd and 3rd lines of therapy.
The role of mTOR inhibitors versus vascular endothelial growth factor pathway inhibitors in the sequential therapy of mRCC is the subject of many discussions among experts.